Cannara Biotech Inc.
LOVE.V
TSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.78% | 21.83% | 35.70% | 26.34% | 27.49% |
| Total Other Revenue | -71.55% | 265.93% | -- | -- | 101.92% |
| Total Revenue | 18.36% | 22.81% | 35.70% | 26.34% | 27.71% |
| Cost of Revenue | 25.09% | 27.95% | 11.27% | -11.63% | 31.40% |
| Gross Profit | 8.52% | 16.71% | 80.35% | 169.61% | 22.67% |
| SG&A Expenses | 42.67% | 24.72% | 14.19% | -4.91% | 30.68% |
| Depreciation & Amortization | -6.37% | 55.09% | -9.57% | 16.66% | -31.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.63% | 27.16% | 10.57% | -10.17% | 28.94% |
| Operating Income | -37.10% | 6.13% | 349.19% | 372.44% | 21.99% |
| Income Before Tax | -33.71% | 19.31% | 177.46% | 228.82% | 42.89% |
| Income Tax Expenses | 35.54% | 162.70% | -- | -- | -- |
| Earnings from Continuing Operations | -55.58% | -42.51% | 98.41% | 190.28% | 8.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.58% | -42.51% | 98.41% | 190.28% | 8.60% |
| EBIT | -37.10% | 6.13% | 349.19% | 372.44% | 21.99% |
| EBITDA | -27.34% | 11.58% | 164.79% | 1,268.20% | 13.43% |
| EPS Basic | -57.53% | -43.47% | 95.15% | 189.82% | 8.77% |
| Normalized Basic EPS | -35.95% | 16.28% | 28,300.00% | 227.93% | 42.99% |
| EPS Diluted | -61.29% | -50.00% | 93.20% | 185.91% | 27.40% |
| Normalized Diluted EPS | -37.09% | 15.38% | 27,900.00% | 225.70% | 42.45% |
| Average Basic Shares Outstanding | 4.11% | 1.58% | 1.57% | 0.60% | -0.22% |
| Average Diluted Shares Outstanding | 5.02% | 2.03% | 1.18% | 2.48% | 0.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |